• Orexo reported first preclinical in vivo pharmacokinetic results for an oral semaglutide tablet using its AmorphOX technology.
• Lead formulation delivered bioavailability comparable to a reference tablet before any formulation optimization.
• Program moves into optimization with an industry partner, targeting bioavailability that could beat marketed oral alternatives.
• Work also evaluates other AmorphOX-based delivery routes, including intranasal formulations, to support needle-free dosing of semaglutide-class peptides.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on October 14, 2026, and is solely responsible for the information contained therein.